NeuroOne Medical Technologies (NASDAQ: NMTC) reported insider sales this month as Business Development Director Mark Christianson moved a portion of his holdings in two transactions. The trades took place on March 10 and March 11, 2026, and together totaled $10,976.
The March 10 transaction consisted of 11,611 shares, while a second sale on March 11 involved 2,109 shares. The reported per-share price for these sales was $0.8, with intraday executions on March 10 occurring between $0.80 and $0.8102, and on March 11 ranging from $0.80 to $0.805. After those dispositions, Christianson is recorded as directly owning 215,200 shares of NeuroOne.
At the time of the filings, NMTC was trading at $0.79, close to InvestingPro's quoted Fair Value of $0.82. The company carries a market capitalization of $40.2 million, and InvestingPro highlights a year-over-year revenue increase of 104% over the last twelve months, while also noting that the business is depleting cash at a rapid pace.
NeuroOne also released its financial results for Q1 Fiscal 2026. The company posted a net loss of $1.4 million, or $0.03 per share, a result that was less negative than the consensus expectation of -$0.04 per share. Quarterly revenue came in at $2.9 million, slightly above the forecasted $2.86 million.
Management reported material gains in product sales over the past fiscal year. Product revenue rose from $3.5 million in fiscal 2024 to $9.1 million in fiscal 2025, with the increase attributed primarily to sales of the OneRF Ablation System.
On the research front, Jones Trading has initiated coverage of NeuroOne with a Buy rating and a price target of $1.50. For investors seeking additional analysis, NeuroOne's Pro Research Report is available through InvestingPro, where it is listed among more than 1,400 reports.
The insider transactions and recent corporate results together present a concise snapshot of activity around NMTC. The sales by Christen- son were executed at prices clustered near the prevailing market price, and the company’s results showed modest beats on earnings and revenue while highlighting both strong product revenue expansion and a continued cash drawdown, according to InvestingPro’s analysis.
Below are the key financial datapoints and recent developments summarized for quick reference:
- Insider sales: 11,611 shares on March 10 and 2,109 shares on March 11, 2026, totaling $10,976.
- Reported sale prices: $0.80 per share reported; March 10 executions ranged $0.80 to $0.8102, March 11 ranged $0.80 to $0.805.
- Post-sale insider holdings: 215,200 shares directly owned by Mark Christianson.
- Market context: NMTC trading at $0.79 vs InvestingPro Fair Value $0.82; market cap $40.2 million.
- Q1 Fiscal 2026: net loss $1.4 million or $0.03 per share, revenue $2.9 million (vs forecast $2.86 million).
- Product revenue growth: $3.5 million (FY 2024) to $9.1 million (FY 2025), led by OneRF Ablation System sales.
- Analyst coverage: Jones Trading initiates with Buy rating and $1.50 price target.
For readers wanting a deeper dive into the company’s financials and projections, NeuroOne’s Pro Research Report is available on InvestingPro among a library of over 1,400 research reports.